Full Press Release Details
NRx Pharmaceuticals Announces Results of the
Vote Held During the Special Meeting of Shareholders
RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc.
(Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced
the results of the vote held during today's Special Meeting of Shareholders.
The meeting was called to vote on a proposal to give the Company's
Board of Directors authority to effect a reverse stock split of all of the outstanding shares of NRx common stock at a ratio in the range
of 1-for-2 to 1-for-15, with such ratio to be determined by the Board in its discretion and included in a public announcement, at a later
date. Despite an active campaign by internet agents to suppress the vote, 61.4% (56,781,354) of all eligible shares were voted, with 94.4%
(53,597,974) of votes cast in favor of the proposal.
"We deeply appreciate and respect the support of our shareholder
base and look forward to continuing to bring hope to life," said Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist
of NRx Pharmaceuticals. "We thank our detractors on the internet and elsewhere who have campaigned tirelessly for our demise and,
in the process, enabled our investors to recognize the potential lifesaving value of our technology. We look forward to sharing our annual
report with shareholders on March 28 and to updating our investors on our ongoing progress."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing
therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression,
chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant
bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the
treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well
as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for
HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical
trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed
under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of
a protocol to treat patients with acute suicidality.
SOURCE NRx Pharmaceuticals, Inc.
For further information: CONTACTS: For further information: CORPORATE
CONTACTS: Jeremy Feffer, LifeSci Advisors, Inc., jfeffer@lifesciadvisors.com; Matthew Duffy, Chief Business Officer, mduffy@nrxpharma.com